CGEM Stock Analysis: Cullinan Oncology | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.205m USD | 12M Return: 155.9% | US2300311063 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.87M
Qual. Beats: -1
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 5.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing therapies for autoimmune diseases and cancer. Its pipeline includes CLN-978 (CD19xCD3 bispecific T cell engager) and velinotamig (BCMAxCD3 bispecific), both in Phase 1 trials for autoimmune diseases, as well as CLN-049 (FLT3xCD3 bispecific) in Phase 1 trials for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also advancing zipalertinib, an oral irreversible EGFR inhibitor, in the Phase 2b REZILIENT1 trial for EGFR ex20ins non-small cell lung cancer.
Cullinan has structured its development strategy around licensing and co-development partnerships, including agreements with Chongqing Genrix Biopharmaceutical (for velinotamig), Taiho Pharmaceutical (for zipalertinib), and Adimab (for antibody discovery and optimization). The company was incorporated in 2016, IPOd in January 2021, and rebranded from Cullinan Oncology to Cullinan Therapeutics in April 2024.
As a clinical-stage biotech, Cullinan does not yet have approved commercial products and relies on pipeline progression, partnership payments, and capital markets to fund its R&D operations. Bispecific T cell engagers, which anchor several of its programs, are an emerging class of immunotherapy designed to bind both a tumor or immune cell target and T cells to drive targeted immune activity.
- Phase 1 data readouts for CLN-978 and velinotamig
- Zipalertinib REZILIENT1 EGFR lung cancer trial advances
- Cash burn raises dilution risk amid R&D spending
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.44 > 0.02 and ΔFCF/TA -10.82 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.44 > 3% & CFO -159.2m > Net Income -204.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.5m) vs 12m ago 4.20% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.83 (Total Current Assets 342.0m - Total Current Liabilities 40.6m) / Total Assets 363.8m |
| B: -1.90 (Retained Earnings -691.5m / Total Assets 363.8m) |
| C: -0.47 (EBIT TTM -208.7m / Avg Total Assets 442.1m) |
| D: 7.65 (Book Value of Equity 321.8m / Total Liabilities 42.0m) |
| Altman-Z'' = 4.10 = AA |
As of August 17, 2026, the stock is trading at USD 20.34 with a total of 558,855 shares traded. Over the past week, the price has changed by +14.72%, over one month by +23.95%, over three months by +36.79% and over the past year by +155.85%.
Current recommended Stop Loss: 18.90 (which is 7.1% or 1.3 ATR below the current price).
Cullinan Oncology has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CGEM.
- StrongBuy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.7 | 56% |
P/E Forward = 6.7385
P/S = 25.8559
P/B = 3.6622
Revenue TTM = 0.0 USD
EBIT TTM = -208.7m USD
EBITDA TTM = -208.4m USD
Long Term Debt = 1.41m USD (estimated: total debt 2.07m - short term 666k)
Short Term Debt = 666k USD (from shortTermDebt, last quarter)
Debt = 2.07m USD (from shortLongTermDebtTotal, last quarter) (leases 2.07m already included)
Net Debt = -332.5m USD (calculated: Debt 2.07m - CCE 334.5m)
Enterprise Value = 872.1m USD (1.20b + Debt 2.07m - CCE 334.5m)
Interest Coverage Ratio = unknown (Ebit TTM -208.7m / Interest Expense TTM 0.0)
EV/FCF = -5.47x (Enterprise Value 872.1m / FCF TTM -159.3m)
FCF Yield = -18.27% (FCF TTM -159.3m / Enterprise Value 872.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 311k) / Revenue TTM)
Tobins Q-Ratio = 2.40 (Enterprise Value 872.1m / Total Assets 363.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.07m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -164.9m (EBIT -208.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.42 (Total Current Assets 342.0m / Total Current Liabilities 40.6m)
Debt / Equity = 0.01 (Debt 2.07m / totalStockholderEquity, last quarter 321.8m)
Debt / EBITDA = 1.60 (negative EBITDA) (Net Debt -332.5m / EBITDA -208.4m)
Debt / FCF = 2.09 (negative FCF - burning cash) (Net Debt -332.5m / FCF TTM -159.3m)
Total Stockholder Equity = 387.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.30% (Net Income -204.7m / Total Assets 363.8m)
RoE = -52.89% (Net Income TTM -204.7m / Total Stockholder Equity 387.0m)
RoCE = -53.74% (EBIT -208.7m / Capital Employed (Equity 387.0m + L.T.Debt 1.41m))
RoIC = -50.92% (negative operating profit) (NOPAT -164.9m / Invested Capital 323.8m)
WACC = 10.37% (E(1.20b)/V(1.21b) * Re(10.39%) + D(2.07m)/V(1.21b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 70.72 | Cagr: 17.22%
[DCF] Fair Price = unknown (Cash Flow -159.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.85 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.86 | Chg30d=+0.81% | Revisions=+17% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.21 | Chg30d=-7.16% | Revisions=-25% | GrowthEPS=+4.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.78 | Chg30d=-9.92% | Revisions=-40% | GrowthEPS=+13.5% | GrowthRev=+163.7%
[Analyst] Revisions Ratio: -22% (up=2, down=4)